Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Pediatric Infectious Disease · Congenital Cytomegalovirus

Newborn Care & Treatment Strategy

At a Glance

Oral valganciclovir is the standard antiviral treatment for symptomatic congenital CMV in newborns. It is given for six months and should ideally be started within the first 30 days of life to prevent worsening of sensorineural hearing loss and other developmental symptoms.

Once a baby is born with a congenital CMV (cCMV) diagnosis, the focus shifts to a detailed evaluation of their health and determining if medical treatment is necessary. This phase involves a coordinated effort by a team of specialists to ensure the best possible long-term outcomes for your child [1][2].

A Note on Breastfeeding

Many parents immediately worry about breastfeeding. It is generally safe and encouraged to breastfeed your baby. Even if the virus is present in your breast milk, passing it postnatally to a full-term baby who already has cCMV will not worsen their condition or cause new cCMV-related issues [3][4]. Always discuss feeding plans with your pediatrician, especially if your baby is born prematurely.

Antiviral Treatment: Valganciclovir

The primary medication used to treat cCMV is oral valganciclovir [2]. This is a liquid antiviral that is typically given at home twice a day [5].

  • Who receives treatment? Antiviral therapy is generally recommended for symptomatic infants—those with signs of the virus at birth, such as a small head size (microcephaly), an enlarged liver or spleen, or abnormal brain imaging [6][7]. Treatment is also often recommended for babies with isolated sensorineural hearing loss (SNHL), as the medication can help prevent the hearing loss from getting worse [8][9].
  • The Critical Time Window: For the treatment to be proven effective, it must generally be initiated within the first 30 days of life (though some recent studies suggest benefits up to 12 weeks) [10][11]. This is a highly time-sensitive issue; parents must advocate for rapid postnatal evaluations to ensure treatment can begin promptly if needed.
  • Duration: The standard course of treatment is 6 months [10][11]. This timeframe has been shown to provide better long-term hearing and developmental benefits than a shorter course.
  • Side Effects: The most common side effect is neutropenia, which is a decrease in a specific type of white blood cell (neutrophils) that helps fight infections [10][12]. Because of this, your baby will need regular blood tests—often weekly at first—to monitor their blood counts [13][14].

Building Your Care Team

Because CMV can affect multiple parts of the body, your baby will likely be followed by several different types of doctors. This multidisciplinary approach ensures that every aspect of your baby’s development is monitored [1][2].

  • Pediatric Infectious Disease (ID) Specialist: Often the “lead” doctor for CMV care, they manage the antiviral medication and monitor the blood tests for side effects [1][2].
  • Audiologist: Performs frequent diagnostic hearing tests to monitor for hearing loss, which can develop or change at any time during childhood [15][16].
  • Pediatric Ophthalmologist: Checks the back of the baby’s eyes for chorioretinitis, which is inflammation or scarring that can affect vision [17][18].
  • Pediatric Neurologist: Evaluates the baby’s brain development and helps manage any neurological symptoms, such as motor delays or seizures [7][6].
  • Early Intervention/Developmental Specialist: Provides support for reaching developmental milestones and can coordinate physical or speech therapy if needed [19][20].

Asymptomatic vs. Symptomatic Monitoring

Regardless of whether your baby starts antiviral medication, long-term monitoring is essential for all children with cCMV:

Group Immediate Action Long-Term Follow-Up
Symptomatic Infants Start 6 months of valganciclovir; baseline imaging (MRI/US) [6][10]. Frequent hearing, vision, and developmental checks for several years [21][22].
Asymptomatic Infants Baseline diagnostic ABR hearing test and eye exam; may consider brain imaging [23][7]. Regular hearing tests (every 3-6 months) to catch late-onset hearing loss [16][24].

Every child’s journey with CMV is different. Your care team will help you navigate these steps based on your baby’s specific needs and test results [1].

Common questions in this guide

Is it safe to breastfeed my baby if they have congenital CMV?
Yes, it is generally safe and encouraged to breastfeed your full-term baby. Even if the virus is present in your breast milk, passing it to a baby who already has cCMV will not worsen their condition or cause new cCMV-related issues.
When is antiviral medication recommended for babies with cCMV?
Oral valganciclovir is typically recommended for symptomatic infants. This includes babies born with signs of the virus such as a small head size, enlarged liver or spleen, abnormal brain imaging, or isolated sensorineural hearing loss.
How soon does cCMV treatment need to start?
For antiviral treatment to be most effective, it should ideally be started within the first 30 days of your baby's life. However, some recent studies suggest there may be benefits up to 12 weeks of age, making rapid evaluation critical.
What are the common side effects of valganciclovir for babies?
The most common side effect is neutropenia, which is a decrease in a specific type of white blood cell that helps fight infections. Because of this, your baby will need regular, often weekly, blood tests to monitor their blood counts.
Which specialist doctors will my baby need to see for cCMV?
Your baby's care team will likely include a pediatric infectious disease specialist to manage medications, an audiologist for frequent hearing tests, a pediatric ophthalmologist to check their vision, and a pediatric neurologist to evaluate brain development.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is my baby's diagnosis considered symptomatic or asymptomatic, and why?
  2. 2.What are the specific benefits and risks of starting oral valganciclovir for my baby?
  3. 3.How often will we need to do blood draws to monitor my baby's white blood cell count (neutrophils)?
  4. 4.If we start antiviral treatment, will it last for 6 months, and what happens if we miss a dose?
  5. 5.Which specialists should my baby see in the first month of life (e.g., infectious disease, ophthalmology, audiology)?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (24)
  1. 1

    The Audiological Follow-Up of Children with Symptomatic Congenital Cytomegalovirus Infection: An Experience in Two Italian Centers.

    Palma S, Forli F, Rossi C, et al.

    Children (Basel, Switzerland) 2023; (10(7)) doi:10.3390/children10071136.

    PMID: 37508638
  2. 2

    Efficacy of Valganciclovir Treatment Depends on the Severity of Hearing Dysfunction in Symptomatic Infants with Congenital Cytomegalovirus Infection.

    Ohyama S, Morioka I, Fukushima S, et al.

    International journal of molecular sciences 2019; (20(6)) doi:10.3390/ijms20061388.

    PMID: 30893926
  3. 3

    Changes in Valganciclovir Use Among Infants with Congenital Cytomegalovirus Diagnosis in the United States, 2009-2015 and 2016-2019.

    Leung J, Grosse SD, Hong K, et al.

    The Journal of pediatrics 2022; (246()):274-278.e2 doi:10.1016/j.jpeds.2022.03.042.

    PMID: 35358586
  4. 4

    Congenital cytomegalovirus: Impact on child health.

    Schleiss MR

    Contemporary pediatrics 2018; (35(7)):16-24.

    PMID: 30740598
  5. 5

    Antiviral treatment in congenital HCMV infection: The six-year experience of a single neonatal center in Poland.

    Jedlińska-Pijanowska D, Czech-Kowalska J, Kłodzińska M, et al.

    Advances in clinical and experimental medicine : official organ Wroclaw Medical University 2020; (29(10)):1161-1167 doi:10.17219/acem/125427.

    PMID: 33053275
  6. 6

    Brain MRI findings in newborns with congenital cytomegalovirus infection: results from a large cohort study.

    Vande Walle C, Keymeulen A, Schiettecatte E, et al.

    European radiology 2021; (31(10)):8001-8010 doi:10.1007/s00330-021-07776-2.

    PMID: 33787973
  7. 7

    Cranial ultrasound and MRI: complementary or not in the diagnostic assessment of children with congenital CMV infection?

    Keymeulen A, De Leenheer E, Casaer A, et al.

    European journal of pediatrics 2022; (181(3)):911-920 doi:10.1007/s00431-021-04273-y.

    PMID: 34636957
  8. 8

    "Minimally symptomatic" congenital cytomegalovirus infection: latest data and emerging concepts.

    Howard A, Nishikawa JK, Sánchez PJ

    Current opinion in pediatrics 2024; (36(4)):480-488 doi:10.1097/MOP.0000000000001364.

    PMID: 38747205
  9. 9

    Valganciclovir in Infants with Hearing Loss and Clinically Inapparent Congenital Cytomegalovirus Infection: A Nonrandomized Controlled Trial.

    Chung PK, Schornagel FAJ, Soede W, et al.

    The Journal of pediatrics 2024; (268()):113945 doi:10.1016/j.jpeds.2024.113945.

    PMID: 38336204
  10. 10

    Ganciclovir and Valganciclovir Use Among Infants With Congenital Cytomegalovirus: Data From a Multicenter Electronic Health Record Dataset in the United States.

    Leung J, Grosse SD, Yockey B, Lanzieri TM

    Journal of the Pediatric Infectious Diseases Society 2022; (11(8)):379-382 doi:10.1093/jpids/piac034.

    PMID: 35532552
  11. 11

    The effect of (val)ganciclovir on hearing in children with congenital cytomegalovirus infection.

    De Cuyper E, Acke F, Keymeulen A, et al.

    International journal of pediatric otorhinolaryngology 2025; (196()):112491 doi:10.1016/j.ijporl.2025.112491.

    PMID: 40682995
  12. 12

    Changes in Neutrophil Count During Valganciclovir Therapy for Symptomatic Congenital Cytomegalovirus Infection.

    Kawamura A, Abe S, Shirai K, et al.

    Biomedicines 2025; (13(7)) doi:10.3390/biomedicines13071739.

    PMID: 40722810
  13. 13

    Hematologic Adverse Events Associated With Prolonged Valganciclovir Treatment in Congenital Cytomegalovirus Infection.

    Ziv L, Yacobovich J, Pardo J, et al.

    The Pediatric infectious disease journal 2019; (38(2)):127-130 doi:10.1097/INF.0000000000002079.

    PMID: 29677086
  14. 14

    Correlation of cytomegalovirus viral load between whole blood and plasma of congenital cytomegalovirus infection under valganciclovir treatment.

    Torii Y, Morioka I, Kakei Y, et al.

    BMC infectious diseases 2023; (23(1)):31 doi:10.1186/s12879-023-07995-6.

    PMID: 36658533
  15. 15

    Cochlear implant performance in children deafened by congenital cytomegalovirus-A systematic review.

    Kraaijenga VJC, Van Houwelingen F, Van der Horst SF, et al.

    Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery 2018; (43(5)):1283-1295 doi:10.1111/coa.13142.

    PMID: 29768731
  16. 16

    The Natural History and Rehabilitative Outcomes of Hearing Loss in Congenital Cytomegalovirus: A Systematic Review.

    Fletcher KT, Horrell EMW, Ayugi J, et al.

    Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology 2018; (39(7)):854-864 doi:10.1097/MAO.0000000000001861.

    PMID: 29912824
  17. 17

    Evaluation and Management of Congenital Cytomegalovirus Infection.

    Coskun E, Kakkar F, Riley LE, et al.

    Obstetrics and gynecology 2025; (145(3)):297-306 doi:10.1097/AOG.0000000000005840.

    PMID: 39847776
  18. 18

    Congenital Cytomegalovirus Infection: From Silent Threat to Vaccine Horizon.

    Moutsopoulou RA, Markou A, Lianou A, et al.

    Vaccines 2025; (13(9)) doi:10.3390/vaccines13090929.

    PMID: 41012132
  19. 19

    Early motor development of children with a congenital cytomegalovirus infection.

    De Kegel A, Maes L, Dhooge I, et al.

    Research in developmental disabilities 2016; (48()):253-61.

    PMID: 26630616
  20. 20

    Short- and long-term neurological outcomes of congenital cytomegalovirus infection.

    Özdemir FMA, Taşçi Yildiz Y, Gümüşer Cinni R, et al.

    Turkish journal of medical sciences 2024; (54(3)):529-536 doi:10.55730/1300-0144.5819.

    PMID: 39050004
  21. 21

    Healthcare costs attributable to congenital cytomegalovirus infection.

    Korndewal MJ, Weltevrede M, van den Akker-van Marle ME, et al.

    Archives of disease in childhood 2018; (103(5)):452-457 doi:10.1136/archdischild-2017-312805.

    PMID: 29363491
  22. 22

    Hearing outcomes in children with Congenital Cytomegalovirus: A multi-center, single-enterprise experience.

    Tapasak B, Cronkite DA, Hustedt-Mai AR, et al.

    International journal of pediatric otorhinolaryngology 2022; (163()):111376 doi:10.1016/j.ijporl.2022.111376.

    PMID: 36370539
  23. 23

    Clinical outcome and the role of antivirals in congenital cytomegalovirus infection.

    Ross SA, Kimberlin D

    Antiviral research 2021; (191()):105083 doi:10.1016/j.antiviral.2021.105083.

    PMID: 33964331
  24. 24

    Audiologic Status of Children with Confirmed Cytomegalovirus Infection: a Case Series.

    Kim JH, Roh KJ, Nam GS, Son EJ

    Journal of Korean medical science 2020; (35(30)):e244 doi:10.3346/jkms.2020.35.e244.

    PMID: 32743988

This page explains congenital CMV newborn care and treatment strategies for educational purposes. Always consult your pediatrician and pediatric infectious disease specialist for your baby's specific medical needs.

Get notified when new evidence is published on Fetal cytomegalovirus syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.